Skeletal Muscle Energy Metabolism in Women With Weight Loss and Ovarian and/or Endometrial Cancer With Weight Loss

Study of Differences in Skeletal Muscle Energy Metabolism Alterations in Women With Weight Loss and Ovarian and/or Endometrial Cancer Based on the Body Mass Index

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT03027479

Acronym

METERMUS-IMC

Enrollment

Registered

2017-01-23

Start date

2017-03-01

Completion date

2019-07-16

Last updated

2025-12-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Endometrial Carcinoma, Ovarian Carcinoma, Weight Loss

Keywords

weight loss, ovarian cancer, endometrial cancer, energy metabolism, Body mass index, obesity, muscle energy

Brief summary

the aim is to study skeletal muscle metabolism alterations métaboliques associated with weight loss in women with ovarian and/or endometrial cancer according to BMI.

Interventions

OTHERSamples

Blood samples, muscle biopsy, adipose tissue samples and ovarian cancer tumor sample

Study design

Allocation

NON_RANDOMIZED

Intervention model

PARALLEL

Primary purpose

HEALTH_SERVICES_RESEARCH

Masking

NONE

Eligibility

Sex/Gender

FEMALE

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

Case group selection criteria: Inclusion Criteria: * Women aged 18 years old and more * Ovarian and/or endometrial cancer * weight loss related to cancer (weight loss \> 5% weight in one month or 10% in 6 months) * Indication to therapeutic surgery * Women affiliated to social security scheme * Women who can understand French and able to sign Informed consent

Exclusion criteria

* Unbalanced Diabetes * Chronic neuromuscular disorder * Any severe uncontrolled medical condition Control group selection criteria: Inclusion Criteria: * Women aged 18 years and more * Surgery Indication for a benign endometrial and/ or ovarian disease * Patient affiliated to social security scheme * Women who can understand French and able to sign Informed consent

Design outcomes

Primary

Measure	Time frame	Description
Measurement of muscle mitochondrial bioenergetics according to BMI	muscle biopsy realized during surgery	Measurement of muscle mitochondrial bioenergetics by high resolution oxygraphy

Secondary

Measure	Time frame	Description
on muscle biopsy	muscle biopsy realized during surgery	* Quantification of lipids on electron microscope * Type of muscular fibers * Analyze of gene expression and proteins involved in 1/ Mitochondrial metabolism 2/ lipid metabolism and 3/ muscular proteolysis by RTqPCR with SyBR Green and Western Blot
on white adipose tissue	adipose tissue samples taken during surgery	adipose tissue composition (fatty acids quantification, sterols, steroids) * RT-qPCR quantification of molecules involved in lipid metabolism (synthesis, transport) and in inflammation (immune profile and cytokines) * RTqPCR analysis, western blot and immunohistochemical expression of markers of transformation into brown adipose tissue * in specific milieu, in vitro experimentation on skeletal muscular cells
on ovarian cancer tumor samples	ovarian tumor biopsies realized during surgery	* lipid composition (fatty acids quantification, sterols, steroids) * RT-qPCR quantification of molecules involved in lipid metabolism (synthesis, transport) and in inflammation (immune profil and cytokines) * culture of tumour cells to evaluate resistance to chemotherapy (platinum)
on computerized tomography	1 day of abdominal CT scan imaging procedure performed at diagnosis	assessment of body composition (fat and muscle compartments)

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 10, 2026